209 related articles for article (PubMed ID: 37092128)
1. Mutations Status of NOTCH Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colorectal Cancer.
Lin A; Yao J; Cheng Q; Liu Z; Luo P; Zhang J
J Inflamm Res; 2023; 16():1693-1709. PubMed ID: 37092128
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Interleukin-1 Signaling Alterations of Colon Adenocarcinoma Identified Implications for Immunotherapy.
Zhou X; Liu Y; Xiang J; Wang Y; Wang Q; Xia J; Chen Y; Bai Y
Front Immunol; 2021; 12():665002. PubMed ID: 34367132
[TBL] [Abstract][Full Text] [Related]
3. Mutations Status of Chemokine Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colon Adenocarcinoma.
Lin A; Xu W; Luo P; Zhang J
Front Pharmacol; 2021; 12():721181. PubMed ID: 34721019
[TBL] [Abstract][Full Text] [Related]
4. The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC.
Li X; Wang Y; Li X; Feng G; Hu S; Bai Y
Front Immunol; 2021; 12():638763. PubMed ID: 34305884
[TBL] [Abstract][Full Text] [Related]
5. Age, sex, and specific gene mutations affect the effects of immune checkpoint inhibitors in colorectal cancer.
Lin A; Zhang H; Hu X; Chen X; Wu G; Luo P; Zhang J
Pharmacol Res; 2020 Sep; 159():105028. PubMed ID: 32569820
[TBL] [Abstract][Full Text] [Related]
6. Effect of TTN Mutations on Immune Microenvironment and Efficacy of Immunotherapy in Lung Adenocarcinoma Patients.
Wang Z; Wang C; Lin S; Yu X
Front Oncol; 2021; 11():725292. PubMed ID: 34513703
[TBL] [Abstract][Full Text] [Related]
7. The Role of SPEN Mutations as Predictive Biomarkers for Immunotherapy Response in Colorectal Cancer: Insights from a Retrospective Cohort Analysis.
Dong Y; Ye S; Li H; Li J; Liu R; Zhu Y
J Pers Med; 2024 Jan; 14(2):. PubMed ID: 38392565
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Analysis Identifies PI3K/Akt Pathway Alternations as an Immune-Related Prognostic Biomarker in Colon Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitor Treatment.
Lin A; Gu T; Hu X; Zhang J; Luo P
J Immunol Res; 2022; 2022():8179799. PubMed ID: 35707003
[TBL] [Abstract][Full Text] [Related]
9. Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors.
Niu Y; Lin A; Luo P; Zhu W; Wei T; Tang R; Guo L; Zhang J
Front Pharmacol; 2020; 11():1213. PubMed ID: 32903385
[TBL] [Abstract][Full Text] [Related]
10. Prognosis of Non-small-cell Lung Cancer Patients With Lipid Metabolism Pathway Alternations to Immunotherapy.
Cheng T; Zhang J; Liu D; Lai G; Wen X
Front Genet; 2021; 12():646362. PubMed ID: 34335679
[TBL] [Abstract][Full Text] [Related]
11. The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer.
Zeng H; Tong F; Bin Y; Peng L; Gao X; Xia X; Yi X; Dong X
Front Immunol; 2022; 13():834142. PubMed ID: 35242138
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma.
Zhang W; Xia H; Yang R; Zhang Y; Zheng Q; Shang X; Liu N; Ma X; Wei C; Chen H; Mu X; Wang X; Liu Y
Front Immunol; 2022; 13():1030969. PubMed ID: 36426352
[TBL] [Abstract][Full Text] [Related]
13. TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Lin A; Zhang H; Meng H; Deng Z; Gu T; Luo P; Zhang J
Front Immunol; 2021; 12():667875. PubMed ID: 34603277
[TBL] [Abstract][Full Text] [Related]
14. PCDH11X mutation as a potential biomarker for immune checkpoint therapies in lung adenocarcinoma.
Liu M; Yang M; Zhang B; Xia S; Zhao J; Yan L; Ren Y; Guo H; Zhao J
J Mol Med (Berl); 2024 May; ():. PubMed ID: 38739269
[TBL] [Abstract][Full Text] [Related]
15. Homologous recombination repair gene mutations in colorectal cancer favors treatment of immune checkpoint inhibitors.
Lin Y; Luo S; Luo M; Lu X; Li Q; Xie M; Huang Y; Liao X; Zhang Y; Li Y; Liang R
Mol Carcinog; 2023 Sep; 62(9):1271-1283. PubMed ID: 37232365
[TBL] [Abstract][Full Text] [Related]
16. DNA Damage Repair Gene Mutations Are Indicative of a Favorable Prognosis in Colorectal Cancer Treated With Immune Checkpoint Inhibitors.
Song Y; Huang J; Liang D; Hu Y; Mao B; Li Q; Sun H; Yang Y; Zhang J; Zhang H; Chen H; Liu H; Zhang S
Front Oncol; 2020; 10():549777. PubMed ID: 33680909
[TBL] [Abstract][Full Text] [Related]
17. B Cell Receptor Signaling Pathway Mutation as Prognosis Predictor of Immune Checkpoint Inhibitors in Lung Adenocarcinoma by Bioinformatic Analysis.
Lin A; Fang J; Cheng Q; Liu Z; Luo P; Zhang J
J Inflamm Res; 2022; 15():5541-5555. PubMed ID: 36176353
[TBL] [Abstract][Full Text] [Related]
18. Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer.
Lin A; Zhang J; Luo P
Front Immunol; 2020; 11():2039. PubMed ID: 32903444
[TBL] [Abstract][Full Text] [Related]
19. CARD11 alteration as a candidate biomarker of skin cutaneous melanoma treated with immune checkpoint blockade.
Si Y; Lin A; Ding W; Meng H; Luo P; Zhang J
Am J Transl Res; 2021; 13(1):286-300. PubMed ID: 33527024
[TBL] [Abstract][Full Text] [Related]
20. Age and Mutations as Predictors of the Response to Immunotherapy in Head and Neck Squamous Cell Cancer.
Zhang Y; Lin A; Li Y; Ding W; Meng H; Luo P; Zhang J
Front Cell Dev Biol; 2020; 8():608969. PubMed ID: 33363171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]